Used as a potent and selective inhibitor in targeted cancer therapies, particularly in the development of kinase inhibitors for oncology research. Its structure enables high-affinity binding to specific protein targets involved in signal transduction pathways, making it valuable in the design of drugs that block tumor growth and proliferation. Commonly employed in the synthesis of covalent inhibitors that target mutant forms of kinases, especially in hematological cancers. Due to its reactive acrylamide group, it forms irreversible bonds with cysteine residues in target proteins, enhancing its duration of action and potency. Widely utilized in preclinical studies to evaluate efficacy, selectivity, and pharmacokinetic properties of novel anti-cancer agents.